InsidersTradesSigma
Follow the 大幸薬品株式会社 share price and the full directors' dealings record of the company, a publicly traded company based in Japan. Shares trade on the JP market, under the supervision of EDINET (Japan FSA). Operating in the Health Care sector, 大幸薬品株式会社 has logged 11 public disclosures. Market capitalisation: €12.7bn. The latest transaction was disclosed on 20 October 2023 (Holding update). Among the most active insiders: Nomura Securities Co.,Ltd.. The full history is accessible without an account.
11
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
13Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 4,029 of 28,551 companies
70.7
score / 100
Value64
Quality78
FCF yld4.0%
Earn yld7.3%
EV/EBITDA11.1x
ROE20%
Gross mgn54%
Net mgn14%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 October 2023
Declarations11 total
ShareXTKSEDINET:S100S1ZX
ShareXTKSEDINET:S100RQNN
0.1% of flowShareXTKSEDINET:S100RQ8G
0.1% of flowShareXTKSEDINET:S100RQ56
99.8% of flowShareXTKSEDINET:S100RF9A
ShareXTKSEDINET:S100RC5A
18.9% of flowShareXTKSEDINET:S100QX4P
13.7% of flowShareXTKSEDINET:S100QULE
15.8% of flowShareXTKSEDINET:S100QO8P
24.6% of flowShareXTKSEDINET:S100QNHZ
27.0% of flowShareXTKSEDINET:S100QGYI
11 of 11 declarations
关于 大幸薬品株式会社
第一制药株式会社是一家日本公司，专注于健康和制药领域。该公司在东京证券交易所上市，股票代码为 XTKS。